​AmeriHealth is constantly evaluating our policies and industry trends to identify opportunities to make specialty drugs more affordable without limiting members' access to life-saving medications.  As a result, AmeriHealth has changed how we manage the colony-stimulating factors (CSFs) drug class.

As of April 1, 2021, AmeriHealth designated the following CSF drugs as preferred products:

• Long-acting CSFs
• Fulphila^® (pegfilgrastim-jmdb)
• Neulasta^® (pegfilgrastim)
• Udenyca^® (pegfilgrastim-cbqv)
• Short-acting CSFs
• Granix^® (tbo-filgrastim)
• Zarxio^® (filgrastim-sndz)

To learn more about these changes and policy updates, please read our announcement article.